|Year : 2016 | Volume
| Issue : 2 | Page : 196-199
The effect of 5-aminosalicylic acid on renal ischemia-reperfusion injury in rats
Department of Physiology, Ardabil University of Medical Sciences, Ardabil, Iran
|Date of Submission||17-Nov-2014|
|Date of Decision||17-Nov-2015|
|Date of Acceptance||17-Feb-2016|
|Date of Web Publication||17-Mar-2016|
Department of Physiology, Ardabil University of Medical Sciences, Ardabil
Source of Support: None, Conflict of Interest: None
Objectives: Ischemia-reperfusion (IR) contributes to the development acute renal failure. Oxygen free radicals are involved in the pathophysiology of IR injury (IRI). This study was designed to investigate the effects of 5-aminosalicylic acid (5-ASA), which is known antioxidant agent, in IR-induced renal injury in rats.
Materials and Methods: Male Wistar albino rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 h of reperfusion. 5-ASA (300 mg/kg, i.p) was administered prior to ischemia. After 24 h reperfusion, urine and blood samples were collected for the determination of creatinine (Cr) and nitric oxide (NO) levels, and renal samples were taken for the histological evaluation.
Results: Treatment with 5-ASA significantly decreased serum Cr and NO levels, also significantly increased urinary Cr level and decreased histopathological changes induced by IR.
Conclusion: Treatment with 5-ASA had a beneficial effect on renal IRI. These results may indicate that 5-ASA exerts nephroprotective effects in renal IRI.
Keywords: 5-aminosalicylic acid, antioxidant, nitric oxide, renal ischemia-reperfusion
|How to cite this article:|
Banaei S. The effect of 5-aminosalicylic acid on renal ischemia-reperfusion injury in rats. Indian J Pharmacol 2016;48:196-9
| » Introduction|| |
Ischemia (cessation of blood flow), followed by reperfusion (re-establishment of blood supply), causes serious damage to organs., Ischemia compromises the continuous supply of oxygen required by tissues to maintain physiological function. Ischemia of kidney is a common problem during kidney transplantation, or hydronephrosis, leading to renal dysfunction and injury. Moreover, when reperfusion is established, additional renal reperfusion injury occurs. This involves the development of oxidative stress via the generation of superoxide anions (O2−). Generation of reactive oxygen species (ROS) such as hydroxyl radical (OH) and O2− as well as reactive nitrogen species (RNS) such as nitric oxide (NO) and peroxynitrite (OONO −) or the decline of antioxidant defense lead to oxidative stress, which plays a critical role in the development of renal ischemia-reperfusion injury (IRI) and ischemic acute renal failure (ARF). The interaction of O2− with NO generates OONO − that causes cellular injury via DNA strand breakage and nitration of tyrosine residues on proteins., NO, OONO − and ROS, cause profound injury to renal cell structures, particularly those of the proximal tubular cell. A major result is ATP depletion, which contributes to renal cell dysfunction and damage. Cell death occurs via a combination of necrosis or apoptosis, depending on the level of oxidative stress. Excessive ROS generation contributes to IRI. ROS scavengers, and antioxidants that remove ROS can protect against renal IRI.
5-aminosalicylic acid (5-ASA), a prescribed drug for ulcerative colitis, is a potent antioxidant and scavenger of oxygen free radicals. 5-ASA, the anti-inflammatory drug commonly used in the treatment of inflammatory bowel diseases, has been shown to possess antioxidant properties considered to be of particular importance in the pathologic context of these diseases. 5-ASA, mesalamine, has superoxide and hydroxyl radical scavenger properties.,
Therefore, ROS and RNS were shown to contribute to the cellular damage induced by ischemia-reperfusion. The aim of the present study was to examine the potential effects of 5-ASA on renal IRI. For this purpose, we measured the levels of NO and creatinine (Cr) and assessed histological changes in rats subjected to renal IRI.
| » Materials and Methods|| |
In this study, twenty male Wistar albino rats (weighing 200–250 g) were obtained from the experimental animal research center, Medical Faculty, Iran University, Iran. The rats were housed in a temperature (21 ± 2°C) and humidity (60 ± 5%) controlled room in which a 12–12 h light-dark cycle was maintained. They had free access to standard water and food. The study was approved by the University Ethics Committee.
Surgery and Experimental Protocol
Under anesthesia (75 mg/kg ketamine hydrochloride and 8 mg/kg xylazine, intraperitoneal injection), right nephrectomy was performed and then, the left renal pedicle (artery and vein) was occluded by placing a microvascular clamp for 45 min to induce ischemia and then placed into metabolite cage, after 24 h reperfusion, urine samples were collected.
The Rats were Divided into Two Groups
• Saline + ischemia-reperfusion (IR) group (control group, n = 10)
• 5-ASA + IR group (n = 10).
5-ASA (Sigma, St. Louis, MO, USA) was administered as a 300 mg/kg single dose, intraperitoneally prior to ischemia.
Urine and blood samples were obtained after 24 h of reperfusion in each group; the left kidneys were removed. The blood samples were centrifuged at approximately 4000 g for 10 min at 4°C. The Cr and NO levels in the serum and urine were measured; the Cr levels were determined to assess the renal function using the Autoanalyzer (Alcyon 300, USA).
Measurement of Nitric Oxide Concentration
Rats under anesthesia were sacrificed after 24 h reperfusion. Serum was obtained from the blood samples. As NO is rapidly oxidized to nitrite and nitrate in biological fluids, nitrite and nitrate concentrations in serum samples were determined as a proxy for NO. Nitrite and nitrate concentrations were measured using a commercial kit according to the manufacture's protocol (R & D Systems). The kit (total NO and nitrite/nitrate parameter assay kit), uses a modified version of the Griess test, a colorimetric assay that measures absorbance at 540 nm. Nitrite and nitrate concentration was calculated using a standard curve and expressed in micromoles (μM) per liter.
The renal tissues were fixed in 10% buffered formalin solution, dehydrated in ascending grades of alcohol, and embedded in paraffin. Sections of 5 μm were taken, stained with hematoxylin-eosin, and examined under a light microscope (Olympus BH-2, Tokyo, Japan) in a blinded manner by a pathologist. Renal tissues were evaluated in terms of tubular lumen dilation, tubular epithelial cell vacuolization, tubular epithelial cell degeneration, and interstitial inflammatory infiltration. Histological changes were scored on a 4-point scale: (−) none, (+) mild, (++) moderate, and (+++) severe damage.
All data are presented as a mean ± standard deviation. Significance testing between groups was performed using one-way analysis of variance with SPSS version 19 and multiple comparison post hoc test to determine significant differences between groups. A P < 0.05 was considered statistically significant.
| » Results|| |
The effect of 5-ASA on renal IRI was investigated in 45 min of renal ischemia followed by 24 h reperfusion. Biochemical analysis results are outlined in [Table 1] and [Table 2], and the results of the histological evaluation are shown in [Table 3].
|Table 3: Tubulointerstitial changes in the kidney after 24 h reperfusion (hematoxylin and eosin stain)|
Click here to view
Effects of 5-aminosalicylic Acid on Kidney Function
Serum Cr level in the 5-ASA + IR group was significantly lower than that in the IR group (P < 0.05). Urinary Cr level in the 5-ASA + IR group was significantly higher than that in the IR group (P < 0.0001).
Effects of 5-aminosalicylic Acid on Nitric Oxide Levels
Serum NO levels in the 5-ASA + IR group were significantly lower than that in the IR group (P < 0.0001). Urinary NO levels in the 5-ASA + IR group were higher than that in the IR group, but the difference was not statistically significant (P > 0.05).
Effects of 5-aminosalicylic Acid on Renal Ischemia-Reperfusion
In the IR group, renal injury was very obvious. There were tubular lumen dilation, vacuolization, degeneration, and mononuclear cell infiltration [Figure 1]a. 5-ASA pretreatment resulted in marked attenuation of tubular lumen dilation, tubular epithelial cell degeneration, vacuolization, and mononuclear cell infiltration induced by IR [Figure 1]b.
|Figure 1: Histopathological evaluation of rat kidneys after 45 min ischemia followed by 24 h reperfusion. Kidney sections are stained by H and E and examined by a light microscope. (a) Tubular lumen dilation (tld), tubular epithelial cell vacuolization (v), tubular epithelial cell degeneration (d), and mononuclear cell infiltration (mci) in the ischemia-reperfusion group (H and E, ×40). (b) The normal renal tissue structure in the 5-aminosalicylic acid group (H and E, ×40)|
Click here to view
A minimum of ten fields for each kidney slide were examined and assigned for severity of changes using scores on a scale of (–) none, (+) mild, (++) moderate, and (+++) severe damage (n = 7 for each group).
| » Discussion|| |
Renal IR is a common result of clinical procedures such as partial nephrectomy, or transplantation. Furthermore, renal IRI is a leading cause of ARF, which is associated with high mortality rates. ARF is characterized by increased vascular resistance in the kidney, a low rate of filtration through the glomeruli, and tubular necrosis. These deleterious effects have been attributed to ROS generation during renal reperfusion., The main sources of free radicals are NO synthase (NOS) and the mitochondrial electron transport chain., NO plays an important role in renal function under both normal and pathophysiologic conditions. Up-regulation of NO may be associated with the cytotoxicity resulting from oxidative stress. Based on this evidence, NO is an important contributor to the pathophysiology of ARF. Our study showed that 5-ASA significantly reduced serum NO levels, which could be protective against renal IRI. NO arises from renal IR, resulting in subsequent tissue injury. A possible mechanism for the protective effect of 5-ASA following renal IR is the reduction of NO levels. Kennedy et al . demonstrated that 5-ASA dose-dependently inhibited NO production. In addition, they concluded that 5-ASA inhibits inducible NOS expression and NO production at therapeutically relevant concentrations. Couto et al . reported that 5-ASA was shown to be a strong scavenger of NO and ONOO −; also, 5-ASA showed the best ROS and RNS scavenging effects.
Our study results indicated that 5-ASA significantly reduced serum Cr level and increased urinary Cr level in rats subjected to renal IR. Based on this, 5-ASA results in an increase of glomerular filtration rate in the kidney and improves renal function after IRI. This beneficial effect may be related to a reduction in NO levels.
In our study, histological evaluation showed that IR caused changes in tubules as shown by tubular lumen dilation, vacuolization, and degeneration. Renal IR also caused an increase in interstitial inflammatory infiltration. 5-ASA severely attenuated the histopathological changes, nearly the normal renal tissue structure was preserved by 5-ASA pretreatment. This cytoprotective effect of 5-ASA may be due to its powerful antioxidant properties.
| » Conclusion|| |
In conclusion, the current study demonstrated that treatment with 5-ASA could prevent renal IRI in a rat model. On the other hand, findings of our study suggest that 5-ASA treatment may exert antioxidant effects by decreasing NO levels. Thus, 5-ASA may have potential as a therapeutic for various clinical conditions involving IRI. However, further studies are required to clarify the exact mechanisms mediating the effect of 5-ASA in renal IRI.
Financial Support and Sponsorship
This study was financially supported by the Iran University of Medical Sciences.
Conflicts of Interest
There are no conflicts of interest.
| » References|| |
Grace PA. Ischaemia-reperfusion injury. Br J Surg 1994;81:637-47.
Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia/reperfusion injury. J Surg Res 2002;105:248-58.
Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, et al.
Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995;59:962-8.
Masztalerz M, Wlodarczyk Z, Czuczejko J, Slupski M, Kedziora J. Superoxide anion as a marker of ischemia-reperfusion injury of the transplanted kidney. Transplant Proc 2006;38:46-8.
Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med 2000;109:665-78.
Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991;288:481-7.
Szabó C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 1996;93:1753-8.
Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: A comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376:1-43.
Glantzounis GK, Salacinski HJ, Yang W, Davidson BR, Seifalian AM. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: A review. Liver Transpl 2005;11:1031-47.
Managlia E, Katzman RB, Brown JB, Barrett TA. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis 2013;19:2051-60.
Simmonds NJ, Millar AD, Blake DR, Rampton DS. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: Assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999;13:363-72.
Hirouchi Y, Kakamu S, Shoji A, Kobayashi K, Enomoto M, Hatakeyama S, et al.
Effects of mesalazine on liver carcinogenesis in medium-term bioassay using rats. J Toxicol Sci 1998;23 Suppl 3:539-52.
Hagiwara S, Koga H, Iwasaka H, Kudo K, Hasegawa A, Kusaka J, et al.
ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model. J Surg Res 2011;171:226-33.
Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntas I, Karahan N, et al.
The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res 2008;149:206-13.
Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000;190:255-66.
Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, et al.
Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 2001;281:F948-57.
Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol 2003;16:63-74.
Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: The relevance to anesthesia practice. Anesth Analg 2005;101:1275-87.
Goligorsky MS, Brodsky SV, Noiri E. Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 2002;61:855-61.
Kennedy M, Wilson L, Szabo C, Salzman AL. 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 1999;4:437-43.
Couto D, Ribeiro D, Freitas M, Gomes A, Lima JL, Fernandes E. Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine. Redox Rep 2010;15:259-67.
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug
| ||Mohammad Beiranvand |
| ||Inflammopharmacology. 2021; 29(5): 1279 |
|[Pubmed] | [DOI]|
||Mechanistic Evaluation of Linalool Effect against Renal Ischemia- Reperfusion Injury in Rats
| ||Mohammad-Ghasem Golmohammadi, Shokofeh Banaei, Ehsan Azimian |
| ||Drug Research. 2021; 71(07): 372 |
|[Pubmed] | [DOI]|
||The Association of Mesalamine With Kidney Disease
| ||Avinash Adiga, David S. Goldfarb |
| ||Advances in Chronic Kidney Disease. 2020; 27(1): 72 |
|[Pubmed] | [DOI]|